Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients

Author:

Garrido Castillo Laura Nalleli1,Anract Julien23ORCID,Delongchamps Nicolas Barry23,Huillard Olivier4ORCID,BenMohamed Fatima1,Decina Alessandra1,Lebret Thierry5,Dachez Roger6,Paterlini-Bréchot Patrizia1ORCID

Affiliation:

1. Rarecells Diagnostics, F-75015 Paris, France

2. National Institute for Health and Medical Research (INSERM), Institut Necker Enfants Malades-INEM, Université Paris Cité, F-75015 Paris, France

3. Service d’Urologie, AP-HP, Hôpital Cochin, F-75014 Paris, France

4. Service de Cancérologie, AP-HP, Hôpital Cochin, F-75014 Paris, France

5. Service d’Onco-Urologie, Hôpital Foch, F-92150 Suresnes, France

6. Innodiag, Pathology Laboratory, F-92100 Boulogne-Billancourt, France

Abstract

Prostate cancer is the third cause of cancer-related deaths in men. Its early and reliable diagnosis is still a public health issue, generating many useless prostate biopsies. Prostate cancer cells detected in urine could be the target of a powerful test but they are considered too rare. By using an approach targeting rare cells, we have analyzed urine from 45 patients with prostate cancer and 43 healthy subjects under 50 y.o. We observed a relevant number of giant cells in patients with cancer. Giant cells, named Polyploid Giant Cancer Cells (PGCC), are thought to be involved in tumorigenesis and treatment resistance. We thus performed immune-morphological studies with cancer-related markers such as α-methylacyl-CoA racemase (AMACR), prostate-specific membrane antigen (PSMA), and telomerase reverse transcriptase (TERT) to understand if the giant cells we found are PGCC or other urinary cells. We found PGCC in the urine of 22 patients, including those with early-stage prostate cancer, and one healthy subject. Although these results are preliminary, they provide, for the first time, clinical evidence that prostate cancers release PGCC into the urine. They are expected to stimulate further studies aimed at understanding the role of urinary PGCC and their possible use as a diagnostic tool and therapeutic target.

Funder

Rarecells Diagnostics

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference45 articles.

1. World Health Organization International Agency for Research on Cancer (IARC) (2023, June 01). GLOBOCAN 2022: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2020. Available online: https://gco.iarc.fr/today/online-analysis.

2. Morphologic features of prostatic adenocarcinoma on ThinPrep® urinary cytology;Tyler;Diagn. Cytopathol.,2011

3. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions;Liu;Semin. Cancer Biol.,2022

4. Circulating giant macrophages as a potential biomarker of solid tumors;Adams;Proc. Natl. Acad. Sci. USA,2014

5. Kasabwala, D.M., Bergan, R.C., Gardner, K.P., Lapidus, R., Tsai, S., Aldakkak, M., and Adams, D.L. (2022). Micronuclei in Circulating Tumor Associated Macrophages Predicts Progression in Advanced Colorectal Cancer. Biomedicines, 10.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3